These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11450615)

  • 21. Etanercept for Crohn's disease.
    Travers SB
    N Engl J Med; 2004 Feb; 350(8):840; author reply 840. PubMed ID: 14973205
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of Crohn disease with anti-tumor necrosis factor alpha].
    Rasmussen SN; Petersen JA
    Ugeskr Laeger; 1999 Jun; 161(26):4026-9. PubMed ID: 10402946
    [No Abstract]   [Full Text] [Related]  

  • 23. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists.
    Chowers Y; Sturm A; Sans M; Papadakis K; Gazouli M; Harbord M; Jahnel J; Mantzaris GJ; Meier J; Mottet C; Peyrin-Biroulet L; Allez M
    J Crohns Colitis; 2010 Oct; 4(4):367-76. PubMed ID: 21122531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDP 571. Anti-TNF monoclonal antibody, BAY 103356.
    Drugs R D; 1999 Mar; 1(3):253-5. PubMed ID: 10566038
    [No Abstract]   [Full Text] [Related]  

  • 25. Infliximab use in children and adolescents with inflammatory bowel disease.
    de Ridder L; Benninga MA; Taminiau JA; Hommes DW; van Deventer SJ
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):3-14. PubMed ID: 17592358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
    MMW Fortschr Med; 2008 Dec; 150(51-52):54-5. PubMed ID: 19156959
    [No Abstract]   [Full Text] [Related]  

  • 27. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
    Moum B
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
    [No Abstract]   [Full Text] [Related]  

  • 28. Tumour necrosis factor and inflammatory bowel disease.
    Armstrong AM; Gardiner KR; Kirk SJ; Halliday MI; Rowlands BJ
    Br J Surg; 1997 Aug; 84(8):1051-8. PubMed ID: 9278640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor inhibitors for inflammatory bowel disease.
    Nielsen OH; Ainsworth MA
    N Engl J Med; 2013 Aug; 369(8):754-62. PubMed ID: 23964937
    [No Abstract]   [Full Text] [Related]  

  • 30. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
    Domènech E; López San Román A; Garcia-Planella E
    Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379
    [No Abstract]   [Full Text] [Related]  

  • 31. Monoclonal antibody use in inflammatory bowel disease.
    Hayes CE; Cerezo CS
    Med Health R I; 2011 Nov; 94(11):337-40. PubMed ID: 22204097
    [No Abstract]   [Full Text] [Related]  

  • 32. [Natural history of inflammatory bowel disease].
    Matsui T
    Nihon Shokakibyo Gakkai Zasshi; 2007 Aug; 104(8):1172-82. PubMed ID: 17675819
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?
    Jorgensen C; Apparailly F; Sany J
    Ann Rheum Dis; 1999 Mar; 58(3):136-41. PubMed ID: 10364909
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease.
    Freudenberg F; Wintergerst U; Roesen-Wolff A; Albert MH; Prell C; Strahm B; Koletzko S; Ehl S; Roos D; Tommasini A; Ventura A; Belohradsky BH; Seger R; Roesler J; Güngör T
    J Allergy Clin Immunol; 2010 Apr; 125(4):943-946.e1. PubMed ID: 20371400
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunogenicity of anti-TNF antibodies. Has the veil been lifted?
    Van Assche G
    Gut; 2011 Mar; 60(3):285-6. PubMed ID: 21193441
    [No Abstract]   [Full Text] [Related]  

  • 36. Cytokine and anti-cytokine therapies for inflammatory bowel disease.
    Ogata H; Hibi T
    Curr Pharm Des; 2003; 9(14):1107-13. PubMed ID: 12769750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biotechnologically manufactured drugs for inflammatory bowel disease.
    Petersen JA; Rasmussen SN
    Scand J Gastroenterol; 2001 Dec; 36(12):1233-8. PubMed ID: 11761010
    [No Abstract]   [Full Text] [Related]  

  • 38. Cytokines in inflammatory bowel diseases - Update 2020.
    Leppkes M; Neurath MF
    Pharmacol Res; 2020 Aug; 158():104835. PubMed ID: 32416212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cytokines and anti-cytokines: therapeutic stakes].
    Emilie D; Galanaud P
    Rev Med Interne; 2000 Oct; 21(10):833-6. PubMed ID: 11075391
    [No Abstract]   [Full Text] [Related]  

  • 40. [Managing inflammatory bowel disease in the biologics era: treating beyond symptoms is not sufficient].
    Peyrin-Biroulet L
    Rev Prat; 2014 Nov; 64(9):1207-9. PubMed ID: 25638855
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.